| Over a week ago | ||||
Cash, cash equivalents… Cash, cash equivalents and marketable securities as of March 31, 2022, were $550.9M. This cash position does not include the additional $37.5M received in April from the tavapadon risk-sharing arrangement. The Company's cash, cash equivalents and marketable securities are expected to continue to support operations into 2024. "Cerevel remains in an enviable position of strength as we seek to transform what is possible in neuroscience," said Tony Coles, chairperson and CEO of Cerevel Therapeutics. "We bring together the highest standard of clinical trial execution with the pipeline, the people, and the capital necessary to deliver new solutions for people living with vexing neuroscience diseases." | ||||
| Over a month ago | ||||
Welcome to "Fly Insider,"…
| ||||
Biotechnology Analyst Yee… Biotechnology Analyst Yee holds a Virtual Meeting with CEO Coles, Chief Scientific Officer Rengerand and Chief Medical Officer Sanchez on March 23 at 1 pm. hosted by Jefferies. | ||||
Biotechnology Analyst Yee… Biotechnology Analyst Yee holds a Virtual Meeting with CEO Coles, Chief Scientific Officer Rengerand and Chief Medical Officer Sanchez on March 23 at 1 pm. hosted by Jefferies. | ||||
The company anticipates… The company anticipates R&D expenses for 2022 to increase relative to 2021, driven by initiation of the comprehensive Phase 2 program for emraclidine; increased costs associated with advancement of the Phase 3 program for tavapadon; continued investment in darigabat, CVL-871 and early discovery efforts; and higher personnel costs to support the growth and advancement of its pipeline. Cerevel expects G&A expenses for 2022 to increase relative to 2021 to support the expansion and advancement of its pipeline and initiate pre-commercialization activities. The company's cash, cash equivalents and marketable securities are expected to continue to support operations into 2024. |
| Over a quarter ago | ||||
Cerevel Therapeutics… Cerevel Therapeutics announced positive results from its Phase 1 healthy volunteer clinical trial to evaluate darigabat, a novel alpha-2/3/5 selective GABAA receptor positive allosteric modulator, or PAM, in acute anxiety. Both the 7.5 mg twice-daily and the 25 mg twice-daily doses of darigabat demonstrated clinically meaningful and statistically significant anxiolytic activity compared with placebo in this proof-of-principle trial. The positive control alprazolam 1 mg twice-daily exhibited placebo-adjusted anxiolytic activity in line with expectations for this trial design. After eight days of treatment, the darigabat 7.5 mg and 25 mg twice-daily doses demonstrated a 3.9 point and 4.5 point placebo-adjusted improvement, respectively, on the primary endpoint of the Panic Symptoms List (PSL-IV) total score. The alprazolam 1 mg twice-daily dose demonstrated a 1.6 point placebo-adjusted improvement on the PSL-IV total score. These positive results were further supported by the secondary endpoint, change in the Fear Visual Analog Scale, which demonstrated a 12.8 point, 7.8 point, and 0.9 point placebo-adjusted improvement for the darigabat 7.5 mg, 25 mg, and alprazolam 1 mg twice-daily doses, respectively. | ||||
Goldman Sachs analyst… Goldman Sachs analyst Madhu Kumar initiated coverage of Cerevel Therapeutics with a Neutral rating and $27 price target. The late clinical-stage CNS therapeutics company's lead asset is tavapadon, which has top-line data from a Phase 3 TEMPO-3 trial expected in the first half of 2023 and top-line data from the Phase 3 TEMPO-1/2 trials due in the second half of next year. While Kumar has "enthusiasm" for several of Cerevel's CNS pipeline prospects, he views the current risk-reward as balanced, the analyst said. | ||||
Biotech Analyst Matteis… Biotech Analyst Matteis holds a conference call with management on January 25 at 2 pm hosted by Stifel. | ||||
Biotech Analyst Matteis… Biotech Analyst Matteis holds a conference call with management on January 25 at 2 pm hosted by Stifel. | ||||
